Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein D-like (HNRNPDL) is an RNA-binding protein belonging to the hnRNP family, which is ubiquitously expressed and involved in the regulation of alternative pre-mRNA splicing, mRNA stability, transport, and the assembly of ribonucleoprotein granules. HNRNPDL contains two RNA recognition motif (RRM) domains and exists as several naturally occurring isoforms due to alternative splicing, with hnRNPDL-2 being predominant in human tissues. The protein localizes to the nucleus and is involved in the formation of functional amyloid fibrils, which are non-toxic and capable of binding nucleic acids. Missense mutations in HNRNPDL are associated with limb-girdle muscular dystrophy D3 (LGMD D3), a rare hereditary disease characterized by progressive proximal muscle weakness. While amyloid formation by certain proteins is often pathological, hnRNPDL-2's amyloid structure is considered functional and may be regulated by alternative splicing of specific exons. HNRNPDL is not currently a direct therapeutic target, and no interacting drugs or clinical biomarkers are established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein D-like (HNRNPDL).